Financial Performance - For the six months ended June 30, 2024, the net loss was $11,543, compared to a net loss of $11,573 for the same period in 2023[61]. - No revenue was generated during the three and six months ended June 30, 2024, while $1,096 was generated in contract research revenue during the same periods in 2023[62]. - Total revenues for the six months ended June 30, 2024, were $0, compared to $1,096 in the same period of 2023, primarily due to the absence of contract research revenue[78]. - Cash used in operating activities for the six months ended June 30, 2024, was $(8,875), an increase from $(6,280) in the same period of 2023[81]. - Net cash provided by financing activities for the six months ended June 30, 2024, was $9,242, compared to $(5) in the prior year, driven by proceeds from a registered direct offering[84]. Research and Development Expenses - Total research and development expenses for the three months ended June 30, 2024, were $3,371, a decrease of 5.3% from $3,559 in the same period of 2023[74]. - The total research and development expenses for the six months ended June 30, 2024, were $6,817, compared to $7,530 for the same period in 2023, reflecting a decrease of 9.5%[65]. - Research and Development (R&D) expenses for the six months ended June 30, 2024, were $6,817, a decrease of 9.5% from $7,530 in the same period of 2023[77]. - Research and development expenses are anticipated to increase over time as product candidates move into later stages of clinical development[66]. General and Administrative Expenses - General and administrative expenses for the three months ended June 30, 2024, were $2,468, down from $2,600 in the same period of 2023[67]. - General and Administrative (G&A) expenses for the six months ended June 30, 2024, were $4,925, down 7.3% from $5,311 in the prior year[77]. Future Outlook and Concerns - The company expects to incur additional operating losses for the foreseeable future and has substantial doubt about its ability to continue as a going concern[61]. - The company has incurred operating losses since inception and does not expect to generate product revenue for many years[62]. - The company expects to incur significant expenses and increasing operating losses for the foreseeable future, particularly related to clinical studies and product development[85]. - There is substantial doubt about the company's ability to continue as a going concern beyond the next twelve months without additional funding[86]. - The company anticipates financing its cash needs through a combination of equity offerings, debt financings, and collaborations[87]. Funding and Cash Position - As of June 30, 2024, the company had unrestricted cash, cash equivalents, and marketable debt securities totaling $14,313[78]. - The company raised a total of $166,907 in gross proceeds from equity securities since inception, with net proceeds of $153,445[78]. - The company relies on collaborations and licensing arrangements to fund operations, which may not be available on acceptable terms[61]. - The company plans to advance MAT2203 into the ORALTO trial for the treatment of invasive aspergillosis, aiming to establish a pharmacodynamic bridge for further indications[58].

BEDMINSTER, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report second quarter 2024 financial results after market close on Wednesday, August 14, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business ...

BEDMINSTER, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces the recent successful treatment of a 22-year-old male with polymicrobial necrotizing fasciitis (flesh-eating disease) that involved drug-resistant Lichtheimia, an angio-invasive species of the fungus Mucorales. This patient was treated at N ...

Dr. David Perlin is the inaugural Chief Scientific Officer and Executive Vice President for the Hackensack Meridian Center for Discovery and Innovation, which seeks to rapidly translate innovations in science to improve outcomes for patients with cancer, infectious diseases, autoimmune and other acute and chronic disorders. He is an expert in drug discovery and drug-resistance mechanisms, and has helped develop novel therapeutics and diagnostics against high-threat bacteria, viruses and fungi. He has publis ...

BEDMINSTER, N.J., May 16, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces new in vitro data showing the use of LNCs for the delivery of small oligonucleotides was presented yesterday in a poster session at TIDES USA 2024: Oligonucleotide & Peptide Therapeutics, a hybrid in-person and virtual conference underway in Boston. T ...

Matinas BioPharma Hldgs (NYSEMKT:MTNB) just reported results for the first quarter of 2024.Matinas BioPharma Hldgs reported earnings per share of -3 cents. This met the analyst estimate for EPS of -3 cents.The company did not report any revenue for the quarter.InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to a ...

Exhibit 99.1 Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update Recent $10 million financing expected to fund planned development programs and operations into the second quarter of 2025 Discussions to secure a partner to advance MAT2203 into the Phase 3 ORALTO trial remain on track Company's strategy to expand its LNC platform into inflammation and oncology supported by favorable in vivo data in multiple disease models Conference call begins at 4:30 p.m. Eastern ti ...

PART I - FINANCIAL INFORMATION This section provides the unaudited condensed consolidated financial statements and management's discussion and analysis for the quarter ended March 31, 2024 [Item 1. FINANCIAL STATEMENTS](index=3&type=section&id=Item%201.%20FINANCIAL%20STATEMENTS) This section presents Matinas BioPharma's unaudited condensed consolidated financial statements and related notes for the quarter ended March 31, 2024 [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This table provides a snapshot of the company's assets, liabilities, and stockholders' equity as of March 31, 2024, and December 31, 2023 | Metric | March 31, 2024 (Unaudited, in thousands) | December 31, 2023 (Audited, in thousands) | | :-------------------------------- | :--------------------------------------- | :-------------------------------------- | | **ASSETS** | | | | Cash and cash equivalents | $1,071 | $4,787 | | Marketable debt securities | $7,039 | $8,969 | | Total current assets | $10,289 | $15,543 | | Total assets | $19,610 | $25,104 | | **LIABILITIES AND STOCKHOLDERS' EQUITY** | | | | Total current liabilities | $1,998 | $2,622 | | Total liabilities | $5,052 | $5,858 | | Total stockholders' equity | $14,558 | $19,246 | | Total liabilities and stockholders' equity | $19,610 | $25,104 | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) This table details the company's revenues, expenses, and net loss for the three months ended March 31, 2024, and 2023 | Metric | Three Months Ended March 31, 2024 (in thousands) | Three Months Ended March 31, 2023 (in thousands) | | :-------------------------------- | :----------------------------------------------- | :----------------------------------------------- | | Contract revenue | $— | $1,096 | | Research and development expenses | $3,446 | $3,970 | | General and administrative expenses | $2,456 | $2,712 | | Total costs and expenses | $5,902 | $6,682 | | Loss from operations | $(5,902) | $(5,586) | | Net loss | $(5,824) | $(5,513) | | Net loss per share – basic and diluted | $(0.03) | $(0.03) | | Comprehensive loss | $(5,737) | $(5,284) | [Condensed Consolidated Statements of Stockholders' Equity](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Stockholders%27%20Equity) This table outlines changes in stockholders' equity, including stock-based compensation and net loss, for the three months ended March 31, 2024 | Metric | Balance, December 31, 2023 (in thousands) | Stock-based compensation (in thousands) | Issuance of common stock (in thousands) | Other comprehensive income (in thousands) | Net loss (in thousands) | Balance, March 31, 2024 (in thousands) | | :-------------------------- | :---------------------------------------- | :-------------------------------------- | :-------------------------------------- | :---------------------------------------- | :---------------------- | :--------------------------------------- | | Total Stockholders' Equity | $19,246 | $995 | $54 | $87 | $(5,824) | $14,558 | [Condensed Consolidated Statements of Cash Flow](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flow) This table summarizes cash flows from operating, investing, and financing activities for the three months ended March 31, 2024, and 2023 | Cash Flow Activity | Three Months Ended March 31, 2024 (in thousands) | Three Months Ended March 31, 2023 (in thousands) | | :-------------------------------- | :----------------------------------------------- | :----------------------------------------------- | | Net cash used in operating activities | $(5,769) | $(4,087) | | Net cash provided by investing activities | $2,000 | $3,000 | | Net cash provided by/(used in) financing activities | $53 | $(4) | | Net decrease in cash, cash equivalents and restricted cash | $(3,716) | $(1,091) | | Cash, cash equivalents and restricted cash at end of period | $1,321 | $5,989 | [Notes to Unaudited Condensed Consolidated Financial Statements](index=8&type=section&id=Notes%20to%20Unaudited%20Condensed%20Consolidated%20Financial%20Statements) This section provides detailed explanations and disclosures supporting the unaudited condensed consolidated financial statements [Note 1 – Description of Business](index=8&type=section&id=Note%201%20%E2%80%93%20Description%20of%20Business) This note describes Matinas BioPharma Holdings Inc. as a clinical-stage biopharmaceutical company - Matinas BioPharma Holdings Inc. is a clinical-stage biopharmaceutical company focused on identifying and developing novel pharmaceutical products[20](index=20&type=chunk) [Note 2 – Liquidity, Plan of Operations and Going Concern](index=8&type=section&id=Note%202%20%E2%80%93%20Liquidity,%20Plan%20of%20Operations%20and%20Going%20Concern) This note addresses the company's liquidity, operational plans, and the substantial doubt regarding its ability to continue as a going concern - The Company has an accumulated deficit of **$181,397 thousand** as of March 31, 2024, and a net loss of **$5,824 thousand** for the three months ended March 31, 2024[21](index=21&type=chunk) - The Company's cash, cash equivalents, and marketable debt securities are not sufficient to fund planned operations beyond the next twelve months, leading to substantial doubt about its ability to continue as a going concern[24](index=24&type=chunk) - Future operations are dependent on controlling operating expenses, proceeds from future common stock sales via ATM, and securing additional financing[25](index=25&type=chunk) [Note 3 – Summary of Significant Accounting Policies](index=9&type=section&id=Note%203%20%E2%80%93%20Summary%20of%20Significant%20Accounting%20Policies) This note outlines the significant accounting policies used in preparing the financial statements, including U.S. GAAP compliance and consolidation principles - The financial statements are prepared in accordance with U.S. GAAP and include consolidated accounts of Holdings and its wholly-owned subsidiaries, with all intercompany transactions eliminated[27](index=27&type=chunk) [Note 4 – Cash, Cash Equivalents, Restricted Cash and Marketable Debt Securities](index=9&type=section&id=Note%204%20%E2%80%93%20Cash,%20Cash%20Equivalents,%20Restricted%20Cash%20and%20Marketable%20Debt%20Securities) This note details the composition and fair value of cash, cash equivalents, restricted cash, and marketable debt securities | Metric | March 31, 2024 (in thousands) | December 31, 2023 (in thousands) | March 31, 2023 (in thousands) | December 31, 2022 (in thousands) | | :------------------------------------------------ | :---------------------------- | :------------------------------- | :---------------------------- | :------------------------------- | | Cash and cash equivalents | $1,071 | $4,787 | $5,739 | $6,830 | | Restricted cash | $250 | $250 | $250 | $250 | | Cash, cash equivalents and restricted cash (Statement of Cash Flows) | $1,321 | $5,037 | $5,989 | $7,080 | | Marketable Debt Securities (March 31, 2024) | Amortized Cost (in thousands) | Unrealized Gain (in thousands) | Unrealized (Loss) (in thousands) | Fair Value (in thousands) | | :------------------------------------------ | :---------------------------- | :----------------------------- | :------------------------------- | :------------------------ | | U.S. Government Notes | $7,173 | $— | $(134) | $7,039 | | Total marketable debt securities | $7,173 | $— | $(134) | $7,039 | - The Company recorded unrealized gains of **$87 thousand** and **$229 thousand** for the three months ended March 31, 2024 and 2023, respectively, on marketable debt securities[32](index=32&type=chunk) [Note 5 - Fair Value Measurements](index=10&type=section&id=Note%205%20-%20Fair%20Value%20Measurements) This note provides information on the fair value hierarchy for marketable debt securities | Fair Value Hierarchy (March 31, 2024) | Total (in thousands) | Level 1 (in thousands) | Level 2 (in thousands) | Level 3 (in thousands) | | :------------------------------------ | :------------------- | :--------------------- | :--------------------- | :--------------------- | | Marketable Debt Securities: U.S. Government Notes | $7,039 | $— | $7,039 | $— | | Total | $7,039 | $— | $7,039 | $— | - U.S. Treasury bonds are classified as Level 1, while U.S. government notes are classified as Level 2 within the fair value hierarchy[38](index=38&type=chunk) [Note 6 – Leasehold Improvements and Equipment](index=11&type=section&id=Note%206%20%E2%80%93%20Leasehold%20Improvements%20and%20Equipment) This note details the net book value of leasehold improvements and equipment, including depreciation and amortization expenses | Category | March 31, 2024 (in thousands) | December 31, 2023 (in thousands) | | :-------------------------------- | :---------------------------- | :------------------------------- | | Equipment | $2,463 | $2,463 | | Leasehold improvements | $1,155 | $1,155 | | Total | $3,618 | $3,618 | | Less: accumulated depreciation and amortization | $1,789 | $1,695 | | Leasehold improvements and equipment, net | $1,829 | $1,923 | - Depreciation and amortization expense was **$94 thousand** for Q1 2024, a slight increase from **$93 thousand** in Q1 2023[39](index=39&type=chunk) [Note 7 – Accrued Expenses and Other Liabilities](index=11&type=section&id=Note%207%20%E2%80%93%20Accrued%20Expenses%20and%20Other%20Liabilities) This note breaks down the components of accrued expenses, including payroll, general and administrative, and research and development | Category | March 31, 2024 (in thousands) | December 31, 2023 (in thousands) | | :-------------------------- | :---------------------------- | :------------------------------- | | Payroll and incentives | $501 | $1,176 | | General and administrative expenses | $223 | $196 | | Research and development expenses | $115 | $75 | | Total accrued expenses | $839 | $1,447 | [Note 8 – Leases](index=11&type=section&id=Note%208%20%E2%80%93%20Leases) This note provides details on operating and finance lease liabilities, including lease expenses and weighted-average terms - Operating lease expense was **$226 thousand** for both Q1 2024 and Q1 2023, while amortization expense on operating lease right-of-use assets was **$145 thousand** in Q1 2024, up from **$132 thousand** in Q1 2023[43](index=43&type=chunk) | Lease Liabilities (March 31, 2024) | Operating Lease Liabilities (in thousands) | Finance Lease Liabilities (in thousands) | | :--------------------------------- | :--------------------------------------- | :--------------------------------------- | | Total undiscounted lease payments | $4,114 | $26 | | Present value of lease liabilities | $3,378 | $21 | | Weighted average remaining lease term (years) | 4.1 | 3.7 | | Weighted average discount rate | 9.2% | 11.6% | [Note 9 – Revenue Recognition, Collaboration Agreements and Other](index=12&type=section&id=Note%209%20%E2%80%93%20Revenue%20Recognition,%20Collaboration%20Agreements%20and%20Other) This note discusses revenue recognition policies and the status of collaboration agreements with BioNTech and Genentech - The BioNTech Agreement, which provided an exclusivity fee of **$2,750 thousand** and funded research expenses, expired on April 8, 2023, with all contract research revenue recognized by March 31, 2023[46](index=46&type=chunk)[47](index=47&type=chunk)[48](index=48&type=chunk) - The Genentech Agreement, involving the development of oral formulations, was completed during Q1 2023, with all obligations fulfilled for the three molecules[49](index=49&type=chunk) [Note 10 – Stockholders' Equity](index=13&type=section&id=Note%2010%20%E2%80%93%20Stockholders%27%20Equity) This note details changes in stockholders' equity, including common stock sales and potentially dilutive securities - The Company sold **218,304 shares** of common stock under its At-The-Market Sales Agreement (ATM) during Q1 2024, compared to zero shares in Q1 2023[50](index=50&type=chunk) | Potentially Dilutive Securities | As of March 31, 2024 | As of March 31, 2023 | | :------------------------------ | :------------------- | :------------------- | | Stock options | 46,031,560 | 34,677,699 | | Warrants | — | 238,000 | | Total | 46,031,560 | 34,915,699 | - Diluted loss per common share is the same as basic loss per common share due to the anti-dilutive effect of potentially dilutive securities[52](index=52&type=chunk) [Note 11 – Accumulated Other Comprehensive Loss](index=13&type=section&id=Note%2011%20%E2%80%93%20Accumulated%20Other%20Comprehensive%20Loss) This note presents the changes in accumulated other comprehensive loss, primarily from unrealized gains on available-for-sale securities | Component | Balance, December 31, 2023 (in thousands) | Net unrealized gain on securities available-for-sale (in thousands) | Balance, March 31, 2024 (in thousands) | | :------------------------------------ | :---------------------------------------- | :---------------------------------------------------------------- | :--------------------------------------- | | Net Unrealized Gain/(Loss) on Available-for-Sale Securities | $(221) | $87 | $(134) | | Accumulated Other Comprehensive Loss | $(221) | $87 | $(134) | [Note 12 – Stock-based Compensation](index=14&type=section&id=Note%2012%20%E2%80%93%20Stock-based%20Compensation) This note outlines stock-based compensation expenses by category and the remaining unrecognized compensation costs | Expense Category | Three Months Ended March 31, 2024 (in thousands) | Three Months Ended March 31, 2023 (in thousands) | | :----------------------- | :----------------------------------------------- | :----------------------------------------------- | | Research and Development | $415 | $553 | | General and Administrative | $580 | $719 | | Total | $995 | $1,272 | - Total compensation costs related to unvested awards not yet recognized were **$6,840 thousand** as of March 31, 2024, with a weighted-average recognition period of **2.4 years**[55](index=55&type=chunk) - The 2013 Equity Compensation Plan expired on May 7, 2024, and the Company intends to adopt a new plan pending shareholder approval[54](index=54&type=chunk) [Note 13 – Subsequent Events](index=14&type=section&id=Note%2013%20%E2%80%93%20Subsequent%20Events) This note discloses significant events occurring after the balance sheet date, including a registered direct offering - On April 5, 2024, the Company completed a registered direct offering, raising approximately **$10,000 thousand** in gross proceeds and **$9,250 thousand** net, from the sale of **33,333,334 shares** of common stock and accompanying warrants[57](index=57&type=chunk) [Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS](index=14&type=section&id=Item%202.%20MANAGEMENT%27S%20DISCUSSION%20AND%20ANALYSIS%20OF%20FINANCIAL%20CONDITION%20AND%20RESULTS%20OF%20OPERATIONS) This section provides management's analysis of the company's financial condition, operational results, and liquidity, including the going concern risk [Overview](index=16&type=section&id=Overview) This overview introduces Matinas BioPharma's strategic focus on its LNC platform and highlights its financial performance and going concern status - Matinas BioPharma is a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies using its proprietary lipid nanocrystal (LNC) platform delivery technology[63](index=63&type=chunk) - Key strategic elements include advancing MAT2203 into the ORALTO trial for invasive aspergillosis, expanding LNC Platform utilization into inflammation and oncology, and building external collaborations with pharmaceutical companies[65](index=65&type=chunk) - The Company incurred net losses of **$5,824 thousand** and **$5,513 thousand** for Q1 2024 and Q1 2023, respectively, and expects continued losses, with substantial doubt about its ability to continue as a going concern[66](index=66&type=chunk) [Financial Operations Overview](index=17&type=section&id=Financial%20Operations%20Overview) This section summarizes key financial trends, including contract revenue decline and expected R&D expense adjustments - Contract research revenue decreased from **$1,096 thousand** in Q1 2023 to **$0** in Q1 2024, as prior collaborations with BioNTech SE and Genentech Inc. concluded[67](index=67&type=chunk) | Expense Category | Three Months Ended March 31, 2024 (in thousands) | Three Months Ended March 31, 2023 (in thousands) | | :-------------------------------- | :----------------------------------------------- | :----------------------------------------------- | | Research and development | $3,446 | $3,970 | | General and administrative | $2,456 | $2,712 | | Total costs and expenses | $5,902 | $6,682 | - R&D expenses are expected to be lower in 2024 compared to 2023 until additional funding is secured for the ORALTO trial and LNC platform advancement[70](index=70&type=chunk) [Results of Operations](index=19&type=section&id=Results%20of%20Operations) This section details the company's revenues and operating expenses, explaining the drivers behind changes in R&D and G&A costs | Metric | Three Months Ended March 31, 2024 (in thousands) | Three Months Ended March 31, 2023 (in thousands) | | :-------------------------- | :----------------------------------------------- | :----------------------------------------------- | | Revenues | $— | $1,096 | | Research and development | $3,446 | $3,970 | | General and administrative | $2,456 | $2,712 | | Operating Expenses | $5,902 | $6,682 | - The decrease in R&D expense was primarily due to lower clinical trial consulting costs and headcount costs[80](index=80&type=chunk) - The decrease in G&A expense was mainly attributable to lower stock-based compensation expense and decreased insurance premiums[81](index=81&type=chunk) [Liquidity and Capital Resources](index=19&type=section&id=Liquidity%20and%20Capital%20Resources) This section discusses the company's cash position, recent financing activities, and ongoing challenges in funding future operations - As of March 31, 2024, the Company had cash, cash equivalents, and marketable debt securities totaling **$8,110 thousand**[83](index=83&type=chunk) - A registered direct offering on April 5, 2024, generated approximately **$9,250 thousand** in net proceeds, but existing funds are still not expected to fund operations beyond the next twelve months, raising substantial doubt about going concern[85](index=85&type=chunk)[91](index=91&type=chunk) | Cash Flow Activity | Three Months Ended March 31, 2024 (in thousands) | Three Months Ended March 31, 2023 (in thousands) | | :-------------------------------- | :----------------------------------------------- | :----------------------------------------------- | | Cash used in operating activities | $(5,769) | $(4,087) | | Cash provided by investing activities | $2,000 | $3,000 | | Cash provided by/(used in) financing activities | $53 | $(4) | | Net decrease in cash, cash equivalents and restricted cash | $(3,716) | $(1,091) | [Off-Balance Sheet Arrangements](index=21&type=section&id=Off-Balance%20Sheet%20Arrangements) This section confirms the absence of any off-balance sheet arrangements for the reported periods - The Company did not have any off-balance sheet arrangements during the periods presented or currently[95](index=95&type=chunk) [Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK](index=21&type=section&id=Item%203.%20QUANTITATIVE%20AND%20QUALITATIVE%20DISCLOSURES%20ABOUT%20MARKET%20RISK) This section states that market risk disclosures are not applicable to the company for the reporting period - This item is not applicable to the Company[96](index=96&type=chunk) [Item 4. CONTROLS AND PROCEDURES](index=21&type=section&id=Item%204.%20CONTROLS%20AND%20PROCEDURES) This section confirms the effectiveness of the company's disclosure controls and procedures and reports no material changes in internal control over financial reporting - The Company's disclosure controls and procedures were evaluated and deemed effective at the reasonable assurance level as of March 31, 2024[97](index=97&type=chunk) - No changes in internal control over financial reporting occurred during Q1 2024 that materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting[100](index=100&type=chunk) PART II - OTHER INFORMATION This section provides additional information not covered in the financial statements, including legal proceedings, risk factors, and exhibits [Item 1. LEGAL PROCEEDINGS](index=23&type=section&id=Item%201.%20LEGAL%20PROCEEDINGS) This section confirms that there are no legal proceedings to report for the company - There are no legal proceedings to report[101](index=101&type=chunk) [Item 1A. RISK FACTORS](index=23&type=section&id=Item%201A.%20RISK%20FACTORS) This section states that there were no material changes to the risk factors previously disclosed in the company's Annual Report on Form 10-K - No material changes from the risk factors set forth in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023[102](index=102&type=chunk) [Item 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS](index=23&type=section&id=Item%202.%20UNREGISTERED%20SALES%20OF%20EQUITY%20SECURITIES%20AND%20USE%20OF%20PROCEEDS) This section reports no unregistered sales of equity securities or use of proceeds to disclose - There are no unregistered sales of equity securities and use of proceeds to report[103](index=103&type=chunk) [Item 3. DEFAULTS UPON SENIOR SECURITIES](index=23&type=section&id=Item%203.%20DEFAULTS%20UPON%20SENIOR%20SECURITIES) This section confirms that there were no defaults upon senior securities - There are no defaults upon senior securities to report[104](index=104&type=chunk) [Item 4. MINE SAFETY DISCLOSURES](index=23&type=section&id=Item%204.%20MINE%20SAFETY%20DISCLOSURES) This section indicates that mine safety disclosures are not applicable to the company - Mine safety disclosures are not applicable[105](index=105&type=chunk) [Item 5. OTHER INFORMATION](index=23&type=section&id=Item%205.%20OTHER%20INFORMATION) This section states that there is no other information to report - There is no other information to report[106](index=106&type=chunk) [Item 6. EXHIBITS](index=23&type=section&id=Item%206.%20EXHIBITS) This section provides an index of exhibits filed or furnished with the Quarterly Report on Form 10-Q - The exhibit index lists documents such as the Certificate of Incorporation, Bylaws, Common Stock Purchase Warrant, Securities Purchase Agreement, Placement Agency Agreement, and certifications from the CEO and CFO[107](index=107&type=chunk)[115](index=115&type=chunk)

BEDMINSTER, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that James J. Ferguson, M.D., Chief Medical Officer of Matinas, will be presenting two abstracts at the ASGCT 27th Annual Meeting being held May 7-11, 2024 in Baltimore highlighting data from ex vivo, in vitro and in vivo studies evaluating the use of ...

BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report first quarter 2024 financial results after market close on Thursday, May 9, 2024. Matinas management will host an investment community conference call and webcast to discuss financial results and provide a business update that day ...